Nektar Therapeutics (NKTR) Cash Flow Statement

The persistent gap where operating cash outflows exceed net losses implies that non-cash charges like depreciation and stock-based compensation are not fully offsetting the cash consumed by operations. This pattern suggests the underlying business is consuming cash at a rate faster than the income statement alone would indicate, reinforcing the severity of the liquidity challenge.

The worsening FCF margin trend is particularly concerning because it occurs alongside a revenue collapse, meaning the company is failing to scale down its cost structure proportionally. This indicates that the fixed-cost R&D platform is not being adjusted quickly enough to match the new, lower-revenue reality, leading to a more severe cash drain per dollar of sales.

The large, negative working capital swings, particularly the -$68.0M in 2026Q1 and -$46.6M in 2026Q2, appear to be a major contributor to the operating cash flow deficit. This pattern may indicate that the company is collecting cash more slowly from partners or is accelerating payments to vendors, both of which would be red flags for a company with a dwindling cash balance.

The absence of any capital deployment to shareholders or for growth capex is a clear signal that all available cash is being directed toward funding operating losses and clinical trials. This posture is typical for a distressed biotech but confirms that the company is in a defensive, capital-preservation mode with no capacity for strategic investments or returns.